Table 2.
Incidence and severity of IRRs and irAEs by tumor type
| Cohort | N | IRRs, n (%) | irAEs, n (%) | ||
| Any grade | Grade ≥3 | Any grade | Grade ≥3 | ||
| NSCLC | 340 | 91 (26.8) | 10 (2.9) | 62 (18.2) | 9 (2.6) |
| GC/GEJC | 282 | 63 (22.3) | 1 (0.4) | 36 (12.8) | 8 (2.8) |
| UC | 249 | 76 (30.5) | 2 (0.8) | 45 (18.1) | 10 (4.0) |
| OC | 228 | 53 (23.2) | 0 | 28 (12.3) | 4 (1.8) |
| MBC | 168 | 30 (17.9) | 0 | 26 (15.5) | 4 (2.4) |
| HNSCC | 153 | 23 (15.0) | 0 | 20 (13.1) | 1 (0.7) |
| MCC | 88 | 19 (21.6) | 0 | 17 (19.3) | 4 (4.5) |
| RCC | 82 | 27 (32.9) | 0 | 16 (19.5) | 2 (2.4) |
| Mesothelioma | 53 | 27 (50.9) | 0 | 13 (24.5) | 4 (7.5) |
| Melanoma | 51 | 18 (35.3) | 0 | 9 (17.6) | 0 |
| ACC | 50 | 13 (26.0) | 0 | 17 (34.0) | 5 (10) |
| CRC | 21 | 8 (38.1) | 0 | 2 (9.5) | 0 |
| CRPC | 18 | 6 (33.3) | 0 | 4 (22.2) | 0 |
ACC, adrenocortical carcinoma; CRC, colorectal cancer; CRPC, castration-resistant prostate cancer; GC/GEJC, gastric cancer or gastroesophageal junction cancer; HNSCC, head and neck squamous cell carcinoma; irAE, immune-related adverse event; IRR, infusion-related reaction; MBC, metastatic breast cancer; MCC, Merkel cell carcinoma; NSCLC, non-small cell lung cancer; OC, ovarian cancer; RCC, renal cell carcinoma; UC, urothelial carcinoma.